Health sync

Get the app. Sync your watch, play the Daily Brief.

Install VitaLonga Sync, allow Apple Health or Health Connect, then scan the QR on Tracker with your phone camera. The Daily Brief keeps playing with the screen locked. File import stays as a fallback. Educational numbers only — not medical advice.

Open Tracker Create a member record

Longevity education

Stay curious about aging well — without pretending to be your clinician.

Read today's research headlines, run honest calculators, keep a private record, and assemble an educational supplement protocol. Not a clinic.

Latest news Open calculators Build your protocol

Today's news

Newest story: 9 Nov 2026

News archive →

Scandinavian Journal of Pain · 9 Nov 2026 · Research

In migraine between attacks, neck and hand pain thresholds were lower when the headaches were not tied to sleep

Scandinavian Journal of Pain published a clinical study on 9 November 2026. Morten Engstrom and colleagues compared pressure pain thresholds at the temple, the neck, the shoulder, and a fingertip, plus heat and cold pain thresholds on the forehead and the palm. The groups were 33 people with migraine between attacks, split into sleep-related and not sleep-related, 20 people with tension-type headache, split into episodic and chronic, and controls matched on age and sex. The abstract used here does not give the size of each split or the ages. People with migraine that was not sleep-related had lower pressure thresholds at the splenius (p = 0.001) and trapezius (p = 0.011) and lower heat (p = 0.009) and cold (p = 0.031) thresholds on the palm than controls. In that same group, a slow-burst index from overnight sleep recording lined up inversely with heat thresholds on the palm and the forehead (rho to -0.57, p at or under 0.04). In episodic tension-type headache, more deep sleep lined up with a higher cold threshold on the forehead (rho = 0.86, p = 0.01) and a higher fingertip pressure threshold (rho = 0.76, p = 0.03). This is an association between sleep physiology and pain thresholds. It is not a sleep plan. DOI 10.1515/sjpain-2026-0031. Not medical advice.

Read at Scandinavian Journal of Pain →Our summary ♡ Save

study
sleep

Circulation · 8 Nov 2026 · Supplements / medicine

In 65 people with heart failure and a preserved ejection fraction, one intravenous iron dose raised peak oxygen uptake at 12 weeks

Circulation published a double-blind randomized trial on 8 November 2026. Gregory D. Lewis, Rajeev Malhotra, and colleagues enrolled people with heart failure and a preserved ejection fraction who also had iron deficiency, defined as ferritin under 100 ng/mL or under 300 ng/mL with transferrin saturation under 20 percent. Enrollment ran from December 2021 through April 2026. 44 people received one intravenous dose of ferric derisomaltose, 1000 mg, and 21 received placebo. Median age was 68 years (IQR 58 to 76), and 72 percent were women. 64 of 65 people finished the 12-week visit. Median baseline peak oxygen uptake was 12.7 mL per kg per minute (IQR 10.6 to 15.8) with iron and 12.2 (11.6 to 14.6) with placebo. At 12 weeks, peak oxygen uptake rose by 1.2 (95 percent CI 0.6 to 1.7) with iron and was unchanged with placebo, 0.1 (-0.7 to 0.9). The least-squares mean difference was 1.1 (0.2 to 1.9, P = 0.02). Oxygen uptake at the anaerobic threshold, 6-minute walk distance, and New York Heart Association class also moved in favor of iron (all P under 0.05). The Kansas City Cardiomyopathy Questionnaire overall summary score did not differ (iron +4.4, -2.4 to 11.2, P = 0.20). Transferrin saturation rose by 9.4 percentage points (4.9 to 13.9) and ferritin by 183 ng/mL (128 to 238) versus placebo. No serious adverse event was tied to the iron dose. The trial conclusion is that this iron dose improved several measures of exercise capacity. Ferric derisomaltose is a prescribed intravenous product. This card does not say anyone should start it. Registration NCT04945707. DOI 10.1161/CIRCULATIONAHA.126.084009. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Read at Circulation →Our summary ♡ Save

study
fitness
off-label-context

Research in Sports Medicine · 8 Nov 2026 · Exercise

In 80 adults with knee osteoarthritis, 12 weeks of remote resistance-band work after one injection improved function, and not pain scores

A randomized add-on trial was published on 8 November 2026. Hui-Ju Lin, Nai-Jen Chang, and colleagues enrolled 80 adults with knee osteoarthritis, Kellgren-Lawrence grade 1 to 3, who had not responded adequately to conservative care. The abstract used here does not give age or sex. Everyone received one hyaluronic acid injection in the joint. They were then allocated to 12 weeks of tele-supervised resistance-band work or to standard education without supervised exercise. The between-group difference in WOMAC total change favored the band program, -5 points (95 percent CI -9.86 to -0.13, p = 0.044). WOMAC physical function also favored the bands (-4.88, -8.28 to -1.47), as did the 30-second sit-to-stand test (+3.79 repetitions, 2.80 to 4.79) and the timed up-and-go (-1.87 seconds, -2.34 to -1.41). Pain on a visual scale did not differ (-0.38, -1.00 to 0.25). The trial conclusion is that adding the remote band program improved function and mobility, with no additional reduction in pain. DOI 10.1080/15438627.2026.2755388. Not medical advice.

Read at Research in Sports Medicine →Our summary ♡ Save